At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Apr 6, 2026 at 10:53 ET
Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per share, raising approximately $345 million in gross proceeds. The capital will support the company's clinical-stage biotech pipeline focused on mast cell biology and immune system therapeutics.
- Celldex closed a public offering of 11,896,750 common shares, including full exercise of the underwriters' option for 1,551,750 additional shares.
- Offering price was $29.00 per share, resulting in gross proceeds of approximately $345 million.
- Proceeds will be used for general corporate purposes, including advancing Celldex’s clinical-stage pipeline in inflammatory, allergic, and autoimmune diseases.
- Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor acted as joint bookrunners; LifeSci Capital and H.C. Wainwright as co-lead managers.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access